Chemours reported a net loss of $29 million in Q1 2026, compared to a $5 million loss in the prior year, mainly due to higher financing and administrative costs. Despite this, the company achieved a 1% increase in net sales to $1.4 billion, driven by record growth in its Thermal & Specialized Solutions segment, especially in Opteon™ and Freon™ refrigerants. Chemours also received $287 million from selling part of its Kuan Yin property, enabling debt repayment and improving liquidity. The company expects Q2 sales to rise 15-20% sequentially and projects full-year sales growth of 3-5%, with ongoing focus on flexible strategies and cost improvements.
The 2026 State of Sustainable Fleets Market Brief reveals that commercial fleets are adapting to a third year of freight recession and major federal policy changes by diversifying powertrain technologies and fuels. Despite federal funding cuts and ta...
Therini Bio has started dosing patients in a Phase 1b trial for THN391, a novel antibody targeting fibrin-driven inflammation in diabetic macular edema (DME). This therapy aims to reduce neuroinflammation and retinal degeneration without affecting bl...
ResVR has introduced an AI-powered assistant integrated into its 3D virtual homebuying platform, enabling buyers to navigate, customize, and make decisions with real-time voice interaction. This assistant offers 24/7 support, multi-language accessibi...
China's securities regulator fined online brokerages Futu and UP Fintech a combined $331 million for operating unlicensed cross-border stock trading services. While both companies must wind down their China operations, the penalties remove a long-sta...
Privia Health Group, a national physician enablement company, announced its expansion into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a large neurology practice with 25 clinicians. NGBC will anchor the new Privia M...
